Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

Aug. 6, 2024 — An AI-based analysis of over 2 million hospital visits has found that most of the time, a pneumonia diagnosis made in the hospital will change from a patient's entrance to their ...

Clinicians discuss the rapidly evolving therapies, technology, and surgical approaches for early-stage NSCLC and take a fresh look at the future of care. Teamwork: A Multidisciplinary Approach to ...

Health care systems that adopted a higher volume of telehealth services less frequently used several low-value screening and diagnostic tests, according to results of a cohort study published in ...

BCD abrdn Bloomberg All Commodity Longer Dated Strategy K-1 Free ETF ...

1. Newman DK, Cumbee RP, Rovner ES. Indwelling (transurethral and suprapubic) catheters. In: Newman DK, Rovner ES, Wein AJ, editors. Clinical Application of Urologic ...